Sunday, October 31, 2010

Diabetes - the challenges of humanity

 Insulin secretagogues
these drugs is the same as earlier applications biguanide oral hypoglycemic drugs, a wide range of clinical use, mainly for their pharmacological type II diabetes insulin secretion, according to chemical structure and role of the different characteristics is also divided into two categories, namely, sulfonylurea (Sulfonylurea) and nateglinide Class (Nateglinide), a total of 7 drugs in clinical use, the total share of oral antidiabetic drugs accounted for 39.6%, nearly five years (2003-2008) average growth rate of 16.8%, but a relatively new class of nateglinide is much higher than the market growth rate is relatively more mature sulfonylurea growth rate. the specific circumstances are detailed below:
1)
sulfonylurea sulfonylureas in clinical use at present there are five kinds of drugs are: (1), glibenclamide (Glibenclamide) ; (2) Gliclazide (Gliclazide); (3) Glimepiride (Glimepiride); (4) Glipizide (Glipizide); (5) gliquidone (Gliquidone). The first 4 species are belong to the second generation sulfonylurea, and Glimepiride is a new generation of long-acting hypoglycemic drugs more.
(1)
glibenclamide glibenclamide is the older generations sulfonylurea drugs, many domestic manufacturers, with sales channels in the hospital about 30 companies, the overall sales and market share have decreased year by year, the largest terminal in the clinical Tianjin Pacific Pharmaceutical (not listed), but also not only the scale of millions, largely glibenclamide is slowly will gradually exit the terminal from the hospital cheap drugs.
the Ministry of Health recently investigated after adding glibenclamide in patients with low blood sugar caused by induced death, because of China's deep-seated reasons for the health care system, unless the future of drug pricing system, radical reform of hospital procurement system, similar to glibenclamide or very inexpensive drugs such future trend is to make space in a variety of higher prices. Guangzhou Pharmaceutical (600332 CH) of Xiaoke Pill which is added to glibenclamide, and its future development depend on access to essential medicines can only be obtained after a stable directory growth and become a mature and stable species, is difficult to expect further rapid growth.
(2) Gliclazide Gliclazide
insulin secretagogue agents occupy the entire 20% share, second only reggae bar 34% of Chennai. The leading brand in the French category Shi Ya CD (not listed) gliclazide (Diamicron), gliclazide is the original research of its manufacturers, Shi Ya CD to reach the United States in 1985, Kang into China,Bailey UGG boots, so far still Home 89% share of the category, and the remaining 11% of the share divided by the more than 40 domestic enterprises, listed companies in the North China Pharmaceutical (600812 CH), Lukang Pharmaceutical (600789) and Henry subsidiary Chengdu Henry has the variety, but Delta Kang sales and magnitude of the gap. gliclazide addition to original research of 80mg / Tablets 30mg Specifications, also launched a sustained release dosage form, taken once a day only, which greatly facilitate the patients, which is the foreign pharmaceutical companies in the strategy, product upgrades continued occupation by the market.
domestic companies should learn the Servier from 2005 Chinese Medical Association under the Chinese Diabetes Society study group of insulin secretion (CGIS) jointly set up a Research Achievement Award is the authority of the academic field of diabetes. and Servier, today announced a new addition in 2009, company is using to promote this academic approach to their own interests and domestic interests of the field of academic gurus combined together to form an impregnable market position, domestic competitors only hold a candle.
(3) glimepiride
6 in the existing class of drugs glibenclamide, glimepiride is the latest generation of long-acting hypoglycemic agents, but also among the 6 varieties of our most promising, the category is much room for future development because of its own with the pharmacological effects of many advantages, not only stimulate insulin secretion, but also improve the body used insulin, and insulin and can be used in conjunction with type II diabetes for the stage. As the first half of 2008, the total glimepiride insulin secretagogue agents share for share of 15.8%, nearly 5-year average growth rate up to 52% from 2003 sales of less than 2 million yuan to the rapid growth in the first half of 2008, 150 million yuan.
now China's market some 15 or so companies involved in the category of the competition, the leading brand is still foreign, Aventis (SNY US) of the Ya Moli (Amaryl) 1996 in the U.S. market, into the Chinese market in 2000, from 1H03 sales volume growth of 1 million the first half of 2008, 77 million yuan, nearly 5-year average growth rate of 54.2%, followed by Fosun Pharmaceutical (600196 CH) IMC's the million Jiangsu Su Ping, Ya Moli about half the sales volume for the 36 million yuan, as a small base so the growth rate higher than the Yamo Li, ranked third and fourth respectively in Shandong Dayin Hai Yang Pharmaceutical (not listed) and Sichuan Purdue Pharma (not listed), the two products on the market are earlier than the nations, but now the scale of only a million sales level, we believe that its most likely do not own the market, but choose the wrong dealers do bad market. the future is very likely that Yamo Li and Wan Su Ping constitute double regulations to occupy the category of a product market.
(4) Glipizide
urea forming an interesting contrast with the United States is the grid column pyrazine and gliquidone, these two species, after growth fell in 2006, and even retrogression, and glimepiride the formation of high-growth trend of this consumption he rose. glipizide by Pfizer (PFE US) original research, FDA clearance to market in 1994, was introduced into China in 2001, but so far sales are not billions of dollars, has remained at the scale of 6,7 million. ranked second in Mogadishu Shandong Pharmaceutical (not listed) Gregor pyrazine films, the enterprise is the specification of the whole variety, but sales in the first half of 2008, but never the same period in 2007 fell to 26 million yuan in 2000 million, the third is the Yangtze River Pharmaceutical (not listed) Qin Su, smaller, only 1,000 million. Glipizide of the total insulin secretion agent in China market share of 13%.
(5) gliquidone (Gliquidone)
gliquidone by the well-known pharmaceutical companies Boehringer Ingelheim, Germany (not listed) development in China through its subsidiary Marching Double-Crane Double-Crane Pharmaceutical co-production, trade names sugar fitness level. drug in security features make it more suitable the elderly to use, so the market share is relatively small but relatively stable,UGG bailey button, the total insulin secretagogues for 12% of market share, lower than 13.5% of glipizide. Marching Double-Crane is the leading brand of sugar fitness level, and its billions of dollars after the 2006 sales volume steady at 1 million level, in the first place is 2,3 Tianjin Institute of Pharmaceutical Research and Jilin Heng and pharmaceutical (not listed), suitable for scale than sugar levels are an order of magnitude smaller.
over 5 dose of sulfonylurea insulin secretagogues has been the most important decades of oral hypoglycemic agents, glibenclamide, glimepiride, glipizide GITS (Rui Yi Ning) and gliclazide as the long-acting preparations, a strong hypoglycemic effect; gliquidone, glipizide dosage form for short-acting preparations general, the shorter duration of action, this 5 sulfonylurea drugs in the future will the status of first-line drugs, but its market share is gradually declining trend, from 2003 in the total 38% of oral hypoglycemic drugs, dropped to 24% in 2008, the next three years, managed to maintain an overall 15% growth.
2)
nateglinide nateglinide class is a class of antidiabetic drugs newer class of insulin secretagogue agents. It is better to control than the sulfonylurea meal blood glucose increased, reduce postprandial blood glucose peak, safety, and rarely postprandial hypoglycemia, present mainly repaglinide (Repaglinide), nateglinide (Nateglinide) and Mitiglinide (MItiglinide). the first two in China available in the market, and because of the characteristics of its own future market prospects,Discount UGG boots, in the market place of formation and the trend of each other sulfonylurea drugs, nearly 5 years of oral hypoglycemic agents in the share rising from 03 in 6.4% increased to 08 in 15.3%.
(1) repaglinide
repaglinide by Novo Nordisk (NVO US) and Boehringer Ingelheim jointly developed in 1998 in the United States market, was introduced into China in 2000, the same year, Stockhausen Jiangsu Hengrui medicine unit of raw material and tablets of repaglinide also received SFDA's approval, so far the market is both production and sales of repaglinide. which Novo Nordisk's repaglinide (brand name: repaglinide) occupy the leading position, with sales from the first half of 2003 increased to 52 million yuan rapidly during the first half of 2008 to 2.6 billion, nearly five-year average growth rate was 38%, the growth rate of all classes of oral hypoglycemic drugs the fastest, this product features and Novo Nordisk diabetes drug strong sales channels are inextricably linked, compared with Stockhausen's reggae Chennai column (trade name: Fu to Di) is still very small, second half of 2007 to 2008, sales of the first half of 60 million yuan, Fu to Di and repaglinide, respectively, administrative protection in China in 2006 and expires in 2007, far-sighted domestic enterprises should intensify follow-up.
(2) Nateglinide Nateglinide
by Japan's second-largest pharmaceutical group Astellas Astellas Pharma (4503 TYO ; the former Yamanouchi Pharmaceutical and Fujisawa Pharmaceutical merged from) and Ajinomoto Ajinomoto (2802 TYO) and Roussel Morishjtu jointly developed, Novartis (NVO US) to obtain its global key markets outside of Japan the right to sell, in the United States in 2001, trade name Starlix, entered China in 2004, sales rapidly, to more than double the growth rate increase, when the first half of 2008 sales volume was 40 million yuan, the product manufacturers in Japan are not in the original study China patent, so generic drugs more than the domestic repaglinide, Henry Medicine, Jiangsu IMC, JCTT (not listed), the day side medicine (not listed), Yangtze River Pharmaceutical, and United Laboratories (3933 HK ; buy) are on sale imitation, but the gap between sales volume and Novartis are more than 10 times, just from the growth point of view Henry, the Yangtze River, Fang Chia Tai Pharmaceutical fine and the momentum of better days, in general, it nateglinide melee just entered the market stage, the products of domestic enterprises is only two years later than Novartis, and the strength of the parties involved are not weak, oral diabetes agents on the category of domestic enterprises is likely to win in nateglinide.
5.
insulin and insulin analogue insulin market was high-speed continental
monopoly situation in mainland China the development of insulin off the market? open? Macnaughton Nordisk participation. back in the last century? ten ? on behalf of Novo Nordisk's insulin products to the form of imports into China in 1994? formal entry into the production plant in Tianjin, China, and insulin preparations. After 15? of development, Novo Nordisk's business income in China has accounted for Camp an important part of revenue, according to Novo Nordisk in 2008? report shows China as the representative of the international zone 19% of its revenue, but the fastest growth rate year on year, up 21%, this growth is the Novo Nordisk Camp three times the market growth in Europe, so to?? good service to the Asia-Pacific regional expansion in China, Novo Nordisk 2008? announced plans to invest 400 million U.S. dollars building a new plant in Tianjin, all? introduction to the Chinese market? advanced preparations of insulin analogues.
Lilly is followed by the introduction of Novo Nordisk insulin preparations to the Chinese pharmaceutical giant Eli Lilly as early as 1918, soon after the establishment of the first overseas branch office establishment is located in Shanghai, China, the ever-changing After 70 years, Eli Lilly and return to China in 1993, 1996, China's production base in Suzhou, ground-breaking ceremony for a plant in 1997 to the Chinese market recombinant human insulin (using recombinant DNA technology) products (goods of famous forest Humulin bleeding ), launched in China in 2005 the world's first insulin analogue lispro insulin (secreted products of famous music Humalog).
French pharmaceutical giant Sanofi - aventis (Euronext Paris: SAN; NYSE: SNY) is the introduction of a third insulin to the Chinese market, the enterprise, its research and development of long-acting insulin product mm insulin glargine (trade name: Lantus Lantus) in 2001? U.S. market, three? after the introduction of China. The above three companies are currently in the mainland occupy the market? insulin market dominance of the giant. As 08? December 31, the three together has 95% market share,UGG boots, and the rest? to 5% of the domestic production of insulin the two companies, Tonghua Dongbao (600867 CH ), and Gan Li Pharmaceutical (not listed).
new momentum of rapid development of insulin analogues
currently on the market in China, the technical level of insulin can be divided into low-animal insulin (generation of insulin), while in the end is the use? largest recombinant human insulin (insulin II), high insulin analogues (insulin, also known as third generation) and other three categories, which have animal insulin because of low prices? take over some market share, but up to now market share are almost ignored?? account?, and high insulin analogues in his own excellent properties, compared to the previous two generations? close to human life? adjustment curve? less cause low blood?, which is developing rapidly.
Currently recombinant human insulin (insulin II) is still the mainstream .2008? mainland market insulin hospital Terminal II scale 2.114 billion yuan purchase more than 2004? 733 million when the scale? 3 times the size of this medication growth rate? coincided with?? disease incidence? is a match, but?? growth rate from 55% in 2004? to 2008? of 21%. We think this is the second generation of insulin has a large sales volume, and the rapid development of three generations of insulin secret? related.
2008 年 second generation insulin 2.114 billion yuan in sales volume, Novo Nordisk Novolin products account for about 18 million Lilly Humulin occupied 261 million, compared with domestic enterprises, 089 million yuan Tonghua Dongbao. From 2008 to see year on year growth, Novo Nordisk and Eli Lilly were up 20%, Toho was 44%, three companies of the two on behalf of the nearly 5-year growth rate of insulin is a declining trend.
insulin preparations with a gradual slowdown in the second generation in sharp contrast, the insulin analogue insulin that is three generations in a trend of rapid growth doubling year after year, 2006 size of the market just over a billion in 2008, has reached 622 million yuan was. market participants in addition to the three major foreign-funded enterprises, the affiliate of Tonghua Dongbao Pharmaceutical Li, Beijing is the only one willing to produce three generations of insulin domestic enterprises, while small, Gan Li, hospital medicine in 2008 the amount of terminal procurement of about 25 million yuan. In three generations of the first insulin market share is still occupied, Novo Nordisk, but the situation is not as prominent as the second generation of insulin, Novo Nordisk in 2008 was 324 million purchase of scale, accounting for 54% of the share, the second is Sanofi-Aventis, amounting to 224 million purchase, accounting for 38%, Eli Lilly's excellent small scale bleeding Music , 4800 million, accounting for 8%.
from the growth point of view, slightly higher than Aventis, Novo Nordisk, the former in 2008 year on year growth of 103%, which was 102%. This Aventis competition policy are inseparable, the order in Novo Nordisk and Eli Lilly's insulin market monopoly control open situation, the three generations of insulin as the main product when the product comes into China, in sharp contrast with Eli Lilly, Lilly's priority secretion Music in the United States after the introduction of 9 years in China. In order to further enhance the status of the insulin market, Aventis on April 21, 2009 announced an increase of 9 million U.S. dollars (600 million yuan) investment in economic and technological development in Beijing more when the plant construction area (insulin glargine) pre-filled pre-filling production line. The expanded plant is expected in Beijing will reach 50 million packaging production unit, in order to better meet the growing demand in China and increase domestic diabetes standards. aventis also announced with the Chinese Diabetes Branch of cooperation to carry out a large-scale genetic studies II diabetes by more than 46,000 cases, including diabetic patients and non-diabetic individuals involved. The study in-depth analysis of type II diabetes associated with genes, may help early detection of diabetes at high risk of the study results may provide new diabetes in China to prevent and / or treatment options. such large investments of non-domestic companies can match.
diabetes clinical guidelines must focus on tracking and attention must be focused on tracking
investors and attention to clinical guidelines
investment opportunities in the pharmaceutical sector on the clinical use of drugs hidden in the terminal data from the international context of drug use trends have great influence on the world's major Medical treatment guidelines will be the latest version of the guide is to avoid the production of medical diagnosis and treatment of the personal bias of the proposed impact to the consensus of opinion of many medical experts and evidence-based medicine to evidence-based medical profession to provide a clinical issue appropriate decision to make systematic exposition of the drug combination proposed guidelines and standards are often far-reaching impact on drug use, it is worth tracking and attention. According to the U.S. Pharmaceutical Research and Manufacturers Association (PhRMA) statistics, clinical guidelines for doctors the impact of drug use the main factors of the highest in the fourth.
currently in the field of diabetes guidelines basically be divided into international guidelines, such as the International Diabetes Federation in 2005 to develop the such as the More specific guidelines on the role is regional guides, such as for the U.S. market each year the American Diabetes Association ADA guidelines; for the European region EASD European Diabetes Association annual guides. 2003 Chinese Diabetes Branch organization of domestic experts prepared the first provide diabetes prevention and control guidance. At present, the copies of the latest MRK US), Johnson & Johnson (JNJ US), Seno Feian million PL, without a domestic enterprise) was published at the end of 2007, the next figure is the standard treatment in China II diabetes flow chart:
the domestic pharmaceutical market is slightly different According to the Chinese Pharmaceutical Association's survey data show that choice of doctors in mainland China, the influence of drugs is the biggest academic promotion, access to 86% of the medical options, which doctors participate in academic conferences with the domestic exchange and can only be accumulated continuing education credits for promotions help other titles are not unrelated. so observed in the hospital terminal business promotion efforts is to determine the academic progress of the important aspects of drug sales is a concern.
Development of diabetes drugs and the whole combination
new mechanism of drug research and development in full swing
emphasizing the international medical community should pay more attention while hypoglycemic b cell function on the protection of a growing consensus achieved, the traditional oral hypoglycemic agents can not change the pancreatic b cell function in diabetic patients the continue to decay, so combination therapy, the development of new mechanism drugs, more and more attention.
08 年 GlaxoSmithKline launched in China the metformin and rosiglitazone compound text Damin, the two formulations complementary characteristics of the joint use of the drug is more effective than metformin alone improves insulin sensitivity and protection of the b cells, the drug's market performance and domestic enterprises, we will closely follow up the situation.
present in major European and American enterprises and research institutions in various stages of development of new diabetes drugs more than 100 species, of which most attention is the development of Novo Nordisk's liraglutide (Liraglutide), the drug's mechanism completely different from the existing oral drop sugar drug, its excellent hypoglycemic effect, regardless of their individual applications with other oral hypoglycemic agents or combined with, can quickly and efficiently and sustained reduction in blood sugar and, most importantly, because of its hypoglycemic with a glucose dependent mechanism only in times of high blood glucose levels play a role in the symptoms of hypoglycemia in patients with very low probability, which is the biggest problem sulfonylurea drugs. In addition, the drug can improve b cell function, lower blood pressure, showing the slow progress of diabetes and reduce the potential cardiovascular complications of diabetes. Moreover, most other anti-diabetic drugs, compared liraglutide to help patients lose weight. This set features a variety of effects on an existing diabetes drugs are not available. The drug has now completed phase 3 clinical and in 2008 made a listing application to the FDA.
before the ceremony in the liraglutide is the first to develop this type of mechanism of the drug, Lilly's Byetta has been FDA in 2005 approved the sale period 4, but after the listing of the 6 patients, causing severe pancreatitis, adverse effects of the drug. At present the same type of GlaxoSmithKline and Roche drugs Syncria (ROG VTX) The Taspoglutide are in phase 3 clinical, future drugs that will be the most popular type of new antidiabetic drugs.
Merck has developed a common principle of liraglutide basis, but not the same as another path to achieve DPP-4 inhibitor drugs Januvia and Metformin Januvia and Janumet are compound in the United States in 2007, which Januvia is the first of this type of DPP-4 drugs, after the listing of the performance was very satisfactory, with 2008 sales to more than 13 billion.
almost no area of medicine in blood glucose from Novo Nordisk as
began to study animal insulin, human beings study of diabetes drugs has experienced 80 years of history, the emergence of each new class of drugs are Because the pathogenesis of diabetes with a further understanding, so that each class of drugs also have a clear role in the molecular structure and principles of Chinese medicine is regrettable that the understanding of diabetes still remains in , although present, there are more than 200 antidiabetic traditional Chinese medicine preparations, 6 varieties included in the national health insurance, but in the pharmacology and the West has penetrated to the very different degree of molecular level studies, all of the medicine in the current also did not find hypoglycemic effects of the medicine than the current western medicine, so when pharmacology is not able to form a unique mechanism of its own when it can not carry out effective promotion of academic activities, efforts to promote the sale of the product is weak, we believe that Chinese medicine can play a role in the local lies in the conditioning of diabetic complications and treatment.
mainland China's future development trend of diabetes drug market from the consumer point of view
Drug consumption in China will be basically divided into two levels, high-end major consumer medicines population is representative of the party and government cadres in the civil service groups, independent of their health care costs in general health care system, 80% of the Chinese government spent on the medical expenses of a group who, while another level is the new rural cooperative medical care as the representative of general population of the health care system, including urban residents and workers health care, despite the large number of per capita costs low, the current government's new health care reform is mainly to improve this latter level of health insurance coverage and intensity. generally speaking, we are more optimistic about the previous level of consumer power, and China to support medical care system in the chronic drug is difficult to fundamentally reversed in a short time, which have led to high sales of drugs is far better than ordinary cheap drugs, so from the above point of view various types of antidiabetic drugs We believe that high quality high prices of medicines, such as oral hypoglycemic drugs in the class nateglinide, acarbose, insulin, insulin analogues in the third-generation drugs such as space for future growth and development are more optimistic, and traditional low-cost supply of the general population hypoglycemic drugs such as biguanides, sulfonylurea grew slowly, produced many enterprises, competitive low profits.
compared with oral hypoglycemic agents, we are more optimistic about the market potential of insulin , due to the special nature of diabetes in the whole course of treatment (this also means is his life) need to participate in the guidance of doctors, therefore, the hospital terminal is the main channel of diabetes drug consumption, insulin also mainly through hospital Sales to the patient and the hospital itself is the main channel of diabetes drug sales. Second, the current with the latest clinical data to establish evidence-based medicine, the medical community is increasingly inclined to recommend that patients start early use of insulin, which we believe will greatly facilitate the use of insulin products for the enterprises to bring greater opportunities for development.
industry that
look around the mainland pharmaceutical companies, in the field of oral hypoglycemic drugs Hengrui Medicine (600276.SH) and its associated companies a more comprehensive product line layout, which has a repaglinide, nateglinide, pioglitazone, metformin four varieties. the field is an insulin Tonghua Dongbao (600867.SH) have a certain strength (although the face competition), and its two 3000 kg of insulin production after the completion of major development has been the basis for the preliminary show, but still need to make greater efforts to expand the market. Details of the two ratings will be the company's follow-up report.
Finally cautious reminded that the next 3-5 years the insulin market in China will be doomed to enter a state of intense competition on the market in addition to Figure 26 manufacturers mentioned in 6 of 16 common species, the China State Food and Drug Administration ( SFDA) of the Drug Evaluation Center documents of approval issued insulin biological products and chemical drugs are divided into two categories.
biological products
application for registration under the category of biological products in the category of which (type of biological products mainly for recombinant insulin the synthesis of insulin, is the main clinical application), the drug registration and insulin-related information a total of 219. which registered documents of approval issued 146; approval is completed, in the outgoing state of the 25 documents of approval; in the pending state in the trial of 48 items.
has released documents relating to 146, belonging to 47 types of applications for importing, import re-register 7, the 23 drug types, added 46 application, there are 23 national standards.
Imports up companies mainly:
Sanofi-Aventis (China) Investment Co., Ltd.
Novo Nordisk
Hefei Life Science Park Investment Development Co., Ltd.
Eli Lilly Asia Beijing Office
Bayer HealthCare
domestic manufacturers are:
Tonghua Dongbao Pharmaceutical Co., Ltd.
Biochemical Pharmaceutical Co., Ltd. Jiangsu IMC
Medical Research Ltd. Shanghai New students Zhuhai United Laboratories Co., Ltd.

Sinovac Biotech Engineering Co., Ltd. Shenzhen
Biotechnology Co., Ltd. Beijing Li Gan Fu
of Biological Pharmaceutical Co., Ltd. in Chongqing, Dongguan Polaroid
Health Biotechnology Research and Development Co., Ltd.
Pharmaceutical Co., Ltd. Shandong
new era under the category of application for registration of chemicals in the chemicals category
and insulin-related information has 116 registered. which registered documents of approval issued 62; approval is completed, in the outgoing state of the 24 documents of approval; in the trial pending in 29 states.
has released documents relating to 62, belonging to 11 types of applications for importing, import and then up three, types of drugs 10, 23 added the application, there are 15 national standards.
main imports up companies:
Yin Qi Man
Novo Nordisk
domestic manufacturers are: < br>
Shanghai Institute of Pharmaceutical Industry Biochemical Pharmaceutical Co., Ltd. Jiangsu IMC
Nanjing Yi Bayer Technology Co., Ltd.
Biological Engineering Co., Ltd. Hong Kong Fosse Xing Pharmaceutical Co., Ltd. Beijing Office
< br> Beijing Jinyuan East and Chemical Co., Ltd.

China Pharmaceutical University, Shenyang, Harbin
Green Dragon Pharmaceutical Co., Ltd. and Hunan Pharmaceutical Co., Ltd.
husband Pharmaceutical Co., Ltd.
Lang force Pharmaceutical Co., Ltd. Nanjing Xi Kaifu
no longer
Australian Pharmaceutical Co., Ltd., Wuhan General Health Pharmaceutical Co., Ltd. Nan Kelun Pharmaceutical Co., Ltd. Hunan

Jiangsu Suzhou Pharmaceutical Group Co., Ltd.
Wu Industrial Co., Ltd. Suzhou Pharmaceutical Factory
Hunan Sixth Continental General Pharmaceutical Co., Ltd. of Heilongjiang Province
cell run
Pharmaceutical Co., Ltd. Tianjin Pharmaceutical Co., Ltd.
Black Dragon Jiang Jiangshi Jiaozuo Hubei Pharmaceutical Co., Ltd.
Benny noon Biochemical Pharmaceutical Co., Ltd. Changzhou Pharmaceutical Co., Ltd.

We think that will compete with new factories Dongbao Bayer and Zhuhai Federation, the trend is worth attention to .09 in July Bayer Schering Pharma AG and the Polish insulin producer Bioton Company and its Singapore subsidiary, has signed a supply agreement SciGen, which will be produced Bioton subsidiary company SciLin insulin products in China, the exclusive listing the right to sell in order to enhance its competitive strength diabetes product line, as mentioned earlier has been Bayer's Ekabotang oral hypoglycemic agents in mainland China accounted for a considerable market share, and a sound marketing network and channels, one can imagine its insulin product launch will be quite a lot of new army.
Zhuhai other federal domestic manufacturers of raw materials and formulations of insulin have been sentenced to approval stage, the internal reasons for Food and Drug Administration recently approved new drug of the time in China greatly extended, we expect that there can be no later than 10 years, the results of the first half to the federal sales team and network of existing scale will be a strong competitor Dongbao.
(Applause.)

No comments:

Post a Comment